Pair page
Bromantane with Semax
Mechanism-tag overlap and published literature for Bromantane and Semax, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
actoprotector-adamantane-derivative
acth-analogneuroprotectivenootropic
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Bromantane and Semax have published these mechanism-level observations. Not a co-administration recommendation.
The canonical Russian nootropic pair — Bromantane builds dopamine synthesis capacity over days while Semax / Adamax provide acute intranasal BDNF / cognitive-plasticity signaling. Trophic plus acute: structural support plus neurochemical drive. Widely used in Russian clinical and nootropic communities.
Quick facts
Bromantane
Semax
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2009 | Bromantane | Badyshtov BA, Makhnycheva AL, Kolik LG, Seredenin SB. Efficacy and safety of ladasten for treatment of asthenic disorders. Results of clinical trials. Zh Nevrol Psikhiatr Im S S Korsakova. 2009;109(5):24-28. (Phase III supporting Russian Ladasten approval.) | human trial, Phase 3 |
| 2006 | Bromantane | Vakhitova IuV, Iamidanov RS, Vakhitov VA, Seredenin SB. The effect of ladasten on gene expression in the rat brain. Mol Biol (Mosk). 2006;40(3):385-391. PMID: 16837899. PMID 16837899 | preclinical, in vivo |
| 1995 | Bromantane | Grekhova TV, Gaĭnetdinov RR, Sotnikova TD, Krasnykh LM, Kudrin VS, Sergeeva SA, Morozov IS, Rayevskiĭ KS. The effect of bromantane, a new immunostimulant and actoprotective preparation, on the release and metabolism of dopamine in the dorsal striatum of freely-moving rats. An in… | preclinical, in vivo |
| 1995 | Bromantane | Kudrin VS, Sergeeva SA, Krasnykh LM, Miroshnichenko II, Grekhova TV, Gainetdinov RR. The effect of bromantan on the dopamin- and serotoninergic systems of the rat brain. Eksp Klin Farmakol. 1995;58(4):8-11. PMID: 8555937. (Russian-language primary preclinical paper on neurotrans… PMID 8555937 | preclinical, in vivo |
| 2001 | Bromantane | Spasov AA, Bugaeva LI, Iezhitsa IN. Toxicological profile of adamantane derivatives. Eksp Klin Farmakol. 2001;64(2):77-80. (Toxicological characterization of the adamantane-derivative class.) | mechanism / discovery |
| 2012 | Bromantane | Oliynyk S, Oh S. The pharmacology of actoprotectors: practical application for improvement of mental and physical performance. Biomol Ther (Seoul). 2012;20(5):446-456. PMID: 24009833. (English-language review of the actoprotector class with bromantane as central example.) PMID 24009833 | review |
| 2004 | Bromantane | World Anti-Doping Agency. Prohibited List. International Standard. S6 Stimulants: bromantan. WADA. Various editions 2004–2026. (Continuous inclusion on the prohibited list since inception.) | regulatory / registry |
| 2008 | Bromantane | Voronina TA, Molodavkin GM, Sergeeva SA, Borliakov LM. Analysis of the neurophysiological mechanisms of anxiolytic effects of ladasten and afobazol. Eksp Klin Farmakol. 2008;71(3):3-7. PMID: 18651609. PMID 18651609 | research article |
| 2002 | Bromantane | Yakimovskii AF, Varshavskaya VM. Experimental analysis of psychopharmacological activity of bromantane. Bull Exp Biol Med. 2002;134(1):60-62. PMID: 12459869. PMID 12459869 | research article |
| 2001 | Bromantane | Morozov IS, Ivanova IA, Sergeeva SA, Petrov VI. Bromantan - a new immunostimulant and psychostimulant of the actoprotector series. Eksp Klin Farmakol. 2001;64(2):44-48. PMID: 11396112. PMID 11396112 | research article |
| 2002 | Semax | Skvortsova VI, Platonova IA, Tvorogova TV, Miasoedov NF. Effect of semax on disability and handicap indexes in patients survived carotid ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2002;102(Suppl 5):36-39. | human study |
| 2020 | Semax | Filippenkov IB, Stavchansky VV, Denisova AE, et al. Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats. Genes (Basel). 2020;11(6):681. | preclinical, in vivo |
| 2013 | Semax | Glazova NY, Sebentsova EA, Manchenko DM, et al. Prolonged beneficial effect of neonatal treatment with Semax on the grooming behavior of elderly rats. Bull Exp Biol Med. 2013;155(6):731-733. | preclinical, in vivo |
| 2011 | Semax | Stavchansky VV, Tvorogova TV, Botsina AY, Skvortsova VI, Limborska SA, Myasoedov NF, Dergunova LV. The effect of Semax and its C-end peptide PGP on expression of neurotrophins and their receptors in rat brain during incomplete global ischemia. Mol Biol (Mosk). 2011;45(6):1026-10… | preclinical, in vivo |
| 2010 | Semax | Shadrina M, Kolomin T, Agapova T, et al. Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action. J Mol Neurosci. 2010;41(1):30-35. | preclinical, in vivo |
| 2007 | Semax | Agapova TY, Agniullin YV, Shadrina MI, Shram SI, Slominsky PA, Lymborska SA, Myasoedov NF. Neurotrophin gene expression in rat brain under the action of Semax, an analogue of ACTH(4-10). Neurosci Lett. 2007;417(2):201-205. | preclinical, in vivo |
| 2007 | Semax | Storozheva ZI, Proshin AT, Sherstnev VV, Stolyarov ID, Boĭko AN. Effects of Semax on different forms of learning and memory in adult and aged rats. Bull Exp Biol Med. 2007;143(4):482-485. | preclinical, in vivo |
| 2006 | Semax | Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. J Neurochem. 2006;97 Suppl 1:82-86. PMID: 16635254. PMID 16635254 | preclinical, in vivo |
| 2006 | Semax | Volkova MV, Shadrina MI, Kolomin TA, Dolotov OV, Grivennikov IA, Shaburova EV, Solntseva OS, Myasoedov NF, Limborska SA, Slominsky PA. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54-60.… PMID 16996037 | preclinical, in vivo |
| 1991 | Semax | Potaman VN, Antonova LV, Dubynin VA, et al. Entry of the synthetic ACTH(4-10) analogue into the rat brain following intravenous injection. Neurosci Lett. 1991;130(1):11-13. | preclinical, in vivo |
| 2001 | Semax | Kost NV, Sokolov OY, Gabaeva MV, Grivennikov IA, Andreeva LA, Myasoedov NF, Zozulya AA. [Semax and selank inhibit the enkephalin-degrading enzymes from human serum]. Bioorg Khim. 2001;27(3):180-183. PMID: 11443939. PMID 11443939 | research article |
| 1997 | Semax | Gusev EI, Skvortsova VI, Miasoedov NF, Nezavibatko VN, Zhuravleva EIu, Vanichkin AV. [Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)]. Zh Nevrol Psikhiatr Im S S Korsakova. 1997;97(6):26-34. PMID: 11517472. PMID 11517472 | research article |
Related pair pages
More research context
Frequently asked
Have Bromantane and Semax been studied together?
Researchers have published mechanistic-level co-administration discussion of Bromantane and Semax. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Bromantane and Semax share?
Bromantane and Semax do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of Bromantane and Semax?
Bromantane: Not approved (US). Semax: Not approved. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Bromantane and Semax?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Bromantane profile and the Semax profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026